$1 =
 63.3901 RUR
€1 =
 68.2458 RUR
Search the Archives:
Today is Dec. 9, 2016 12:53 PM (GMT +0300) Moscow
Forum  |  Archive  |  Photo  |  Advertising  |  Subscribe  |  Search  |  PDA  |  RUS
Ad Market to Dip in 2009
Gazprom Builds Big Gas Reservoir
Serbia Lets the Gas In
Peugeot Plans Sales Spike in Russia
Ukraine Ready to Winter With No Gas of ...
Readers' Opinions
You are welcome to share your opinion on the issue.
Aug. 31, 2005
Print  |  E-mail  |  Home
Polish Bioton Comes Bearing Insulin
Polish Bioton has launched construction of insulin works in Orlov Region, Russia. It is the second insulin project that commenced in Russia this year. Investors are lured by the governments program on preferential supply of medicine.
According to RMBC, insulin import to Russia reached $440 million last year. Core suppliers are Danish Novo Nordisk (around 50 percent), Swiss Eli Lilly (30 percent) and French-German Sanofi-Aventis (20 percent).

The actual construction of Bioton producer of insulin began past week. Backed up by Orlov Regions authorities, Bioton Vostok (Russias agency of Bioton) counts on putting the enterprise in operation already in late 2006. Project investments are estimated at 20 million. The ultimate target is to cover around 20 percent of the insulin market of Russia.

It seems worth pointing out that Bioton Vostok is the second insulin project launched this year. In mid-June, Russias Biotek and Chinese Tonghua Dongbau announced they have got down to constructing a similar enterprise in Penza Region to win 30 percent of Russias market once the project is completed.

Until recently, insulin production in Russia was far from profitable. No a single enterprise has been built once the Ministry of Public Health of the former USSR banned law-quality production of insulin in 1989 in favor of the import deliveries.

After the Soviet Unions collapse, large European companies arrived at the insulin market of Russia, having gained complete control over it. In such environment, appearance of a wholesome national producer was impossible, said David Melik-Guseinov, a leading analyst at Pharmexpert.

Todays activity of insulin producers in our country could be attributed to the federal program of additional medicine provision to the residents of Russia, who are entitled to having certain preference in this field. The program covers a third of all pharmaceutical market of Russia and has a sizable budget of $2 billion. Of that amount, around 70 percent of all funds go to the national producers. Therefore, for a Russian insulin maker, the sales market is no trouble now.

All the Article in Russian as of Aug. 31, 2005

Print  |  E-mail  |  Home

Forum  |  Archives  |   Photo  |  About Us  |  Editorial  |  E-Editorial  |  Advertising  |  Subscribe  |  Subscribe to Printed Editions  |  Contact Us  |  RSS
1991-2016 ZAO "Kommersant. Publishing House". All rights reserved.